Reduce involuntary movements with AUSTEDO XR® (deutetrabenazine) tablets treatment for TD. See safety info and boxed warning.

AUSTEDO XR ® (deutetrabenazine) extended-release tablets and AUSTEDO ® (deutetrabenazine) tablets are indicated in adults for the treatment of chorea associated with …

Aug 20, 2025 · Austedo's drug class is a VMAT2 inhibitor (vesicular monoamine transporter 2 inhibitor). Austedo tablets are taken twice daily, and the Austedo XR (extended-release) …

Oct 22, 2025 · Teva Pharmaceuticals announced new data from the ongoing, real-world IMPACT-TD Registry, which demonstrates that treatment with deutetrabenazine tablets or …

Nov 12, 2025 · Austedo standard and XR tablets are currently indicated for adults for the treatment of chorea in Huntington disease and tardive dyskinesia. Austedo is the first VMAT2 …

Once-daily AUSTEDO XR® (deutetrabenazine) extended release tablets reduce uncontrollable Tardive Dyskinesia (TD) body movements. See safety info including Boxed Warning.

The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia. Adverse …

Nov 7, 2025 · Teva Pharmaceuticals presented new findings from the IMPACT-TD Registry indicating that treatment with AUSTEDO and AUSTEDO XR significantly improved the lives of …

Jun 1, 2024 · In a significant advancement for those suffering from tardive dyskinesia (TD), the U.S. Food and Drug Administration (FDA) recently approved Austedo XR (extended-release …

Mar 5, 2024 · Treatments for tardive dyskinesia include deutetrabenazine (Austedo, Austedo XR), valbenzaine (Ingrezza), tetrabenazine (Xenazine), amantadine, vitamin B6 (pyridoxine) and …